Literature DB >> 12663409

Treating generalised anxiety disorder.

Alison Tonks1.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12663409      PMCID: PMC1125601          DOI: 10.1136/bmj.326.7391.700

Source DB:  PubMed          Journal:  BMJ        ISSN: 0959-8138


× No keyword cloud information.
  9 in total

1.  A double-blind, placebo-controlled trial of abecarnil and diazepam in the treatment of patients with generalized anxiety disorder.

Authors:  K Rickels; N DeMartinis; B Aufdembrinke
Journal:  J Clin Psychopharmacol       Date:  2000-02       Impact factor: 3.153

2.  Recovery rates in generalized anxiety disorder following psychological therapy: an analysis of clinically significant change in the STAI-T across outcome studies since 1990.

Authors:  P L Fisher; R C Durham
Journal:  Psychol Med       Date:  1999-11       Impact factor: 7.723

Review 3.  Generalized anxiety disorder: nature and course.

Authors:  H U Wittchen; J Hoyer
Journal:  J Clin Psychiatry       Date:  2001       Impact factor: 4.384

Review 4.  Dissolving the burden of generalized anxiety disorder.

Authors:  P T Ninan
Journal:  J Clin Psychiatry       Date:  2001       Impact factor: 4.384

Review 5.  Patterns and correlates of generalized anxiety disorder in community samples.

Authors:  Ronald C Kessler; Hans-Ulrich Wittchen
Journal:  J Clin Psychiatry       Date:  2002       Impact factor: 4.384

6.  A multidimensional meta-analysis of treatments for depression, panic, and generalized anxiety disorder: an empirical examination of the status of empirically supported therapies.

Authors:  D Westen; K Morrison
Journal:  J Consult Clin Psychol       Date:  2001-12

Review 7.  Generalized anxiety disorder. An important clinical concern.

Authors:  R B Hidalgo; J R Davidson
Journal:  Med Clin North Am       Date:  2001-05       Impact factor: 5.456

Review 8.  Mixed symptoms and syndromes of anxiety and depression: diagnostic, prognostic, and etiologic issues.

Authors:  J G Barbee
Journal:  Ann Clin Psychiatry       Date:  1998-03       Impact factor: 1.567

9.  Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey.

Authors:  R C Kessler; K A McGonagle; S Zhao; C B Nelson; M Hughes; S Eshleman; H U Wittchen; K S Kendler
Journal:  Arch Gen Psychiatry       Date:  1994-01
  9 in total
  6 in total

Review 1.  Psychological therapies for generalised anxiety disorder.

Authors:  V Hunot; R Churchill; M Silva de Lima; V Teixeira
Journal:  Cochrane Database Syst Rev       Date:  2007-01-24

2.  Management of generalized anxiety disorder in primary care: identifying the challenges and unmet needs.

Authors:  Jonathan R T Davidson; Douglas E Feltner; Ashish Dugar
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2010

3.  Identification and characterization of kava-derived compounds mediating TNF-alpha suppression.

Authors:  Michael P Pollastri; Adrian Whitty; Jamie Cassidy Merrill; Xiaoren Tang; Trent D Ashton; Salomon Amar
Journal:  Chem Biol Drug Des       Date:  2009-06-16       Impact factor: 2.817

4.  Chemical composition of the essential oil from kelussia odoratissima Mozaff. and the evaluation of its sedative and anxiolytic effects in mice.

Authors:  Mohammed Rabbani; Seyed Ebrahim Sajjadi; Masoud Sadeghi
Journal:  Clinics (Sao Paulo)       Date:  2011       Impact factor: 2.365

5.  Benzodiazepine prescribing behaviour and attitudes: a survey among general practitioners practicing in northern Thailand.

Authors:  Manit Srisurapanont; Paul Garner; Julia Critchley; Nahathai Wongpakaran
Journal:  BMC Fam Pract       Date:  2005-06-23       Impact factor: 2.497

6.  The homeopathic preparation Nervoheel N can offer an alternative to lorazepam therapy for mild nervous disorders.

Authors:  Lodewijk van den Meerschaut; Andrea Sünder
Journal:  Evid Based Complement Alternat Med       Date:  2007-10-25       Impact factor: 2.629

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.